FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24743-2307US	SERIAL NO. 09/601,997
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Keck *et al.*	
	FILING DATE December 15, 2000	GROUP 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	A	4	9	8	7	0	7	1	01/22/91	Cech *et al.*	435	91	12/03/86
	B	5	0	3	7	7	4	6	08/06/91	Cech *et al.*	435	91	03/16/89
	C	5	0	9	3	2	4	6	03/03/92	Cech *et al.*	435	91	08/03/90
	D	5	1	1	6	7	4	2	05/26/92	Cech *et al.*	435	91	03/24/89
	E	5	1	8	0	8	1	8	01/19/93	Cech *et al.*	536	23.1	03/21/90
	F	5	1	9	0	9	3	1	03/02/93	Inouye	435	91	11/15/89
	G	5	2	1	7	8	7	9	06/08/93	Huang *et al.*	435	69.1	12/27/91
	H	5	2	1	7	8	8	9	06/08/93	Roninson *et al.*	435	172.3	11/19/90
	I	5	2	7	2	0	6	5	12/21/93	Inouye *et al.*	435	91.1	06/21/90
	J	5	3	5	4	6	7	8	10/11/94	Lebkowski *et al.*	435	172.3	12/21/92
	K	5	3	5	4	8	5	5	10/11/94	Cech *et al.*	536	24.1	02/28/92
	L	5	4	5	7	2	8	1	10/10/95	Bridges *et al.*	800	205	09/29/89
	M	5	4	9	6	6	9	8	03/05/96	Draper *et al.*	435	6	12/07/92
	N	5	5	0	4	2	0	0	04/02/96	Hall *et al.*	536	24.1	02/18/94
	O	5	5	8	9	3	6	2	12/31/96	Bujard *et al.*	435	69.1	06/07/95
	P	5	5	9	1	6	1	0	01/07/97	Cech *et al.*	435	91.31	07/21/94
	Q	5	5	9	9	7	0	6	02/04/97	Stinchcomb *et al.*	436	366	09/23/94
	R	5	6	3	1	2	3	6	05/20/97	Woo *et al.*	514	44	08/26/93
	S	5	6	6	7	9	6	9	09/16/97	Sullenger *et al.*	435	6	11/12/93
	T	5	6	7	0	4	8	8	09/23/97	Gregory *et al.*	514	44	11/13/93
	U	5	6	8	6	2	7	9	11/11/97	Finer *et al.*	435	172.3	06/10/94
	V	5	8	5	6	1	8	8	01/05/99	Hampel *et al.*	435	375	06/07/95
	W	6	2	0	4	0	5	2	03/20/01	Bout *et al.*	435	320.1	08/15/95

FOREIGN PATENT DOCUMENTS

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24743-2307US	SERIAL NO. 09/601,997
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Keck *et al.*	
	FILING DATE December 15, 2000	GROUP 1645

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes	Translation No
	X	0	7	0	7	0	7	1	04/17/96	EP (A1)				
	Y	2	3	1	9	7	7	3	06/03/98	GB (A)				
	Z	4	4	2	4	7	6	2	07/27/95	DE (C1)				X*
	AA	9	2	0	1	7	8	6	02/06/92	PCT (A1)				
	AB	9	4	1	3	8	3	3	06/23/94	PCT (A1)				
	AC	9	4	2	0	6	1	8	09/15/94	PCT (A1)				
	AD	9	4	2	6	8	7	7	11/24/94	PCT (A1)				
	AE	9	4	2	8	1	5	2	12/08/94	PCT (A1)				X*
	AF	9	5	1	4	0	9	1	05/26/95	PCT (A2)				
	AG	9	5	1	4	1	0	1	05/26/95	PCT (A1)				X*
	AH	9	5	1	4	1	0	2	05/26/95	PCT (A1)				X*
	AI	9	6	0	1	3	1	4	01/18/96	PCT (A2)				X*
	AJ	9	6	0	5	3	2	1	02/22/96	PCT (A1)				X*
	AK	9	6	0	9	3	9	2	03/28/96	PCT (A1)				
	AL	9	6	3	8	5	5	3	12/05/96	PCT (A1)				
	AM	9	7	0	0	3	2	6	01/03/97	PCT (A1)				
	AN	9	7	2	7	2	1	2	07/31/97	PCT (A1)				
	AO	9	7	2	7	2	1	3	07/31/97	PCT (A1)				
	AP	9	8	3	2	8	8	0	07/30/98	PCT (A1)				
	AQ	9	8	5	0	5	3	0	11/12/98	PCT (A2)				

X* = An English language derwent is provided

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AR	Abraham *et al.*, "Signal transduction through the T-cell antigen receptor," *Trends in Biochemical Sciences* 17: 434-8 (1992).
	AS	Ausubel *et al.* (Eds.), *Current Protocols in Molecular Biology* New York: John Wiley & Sons, 1994.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24743-2307US	SERIAL NO. 09/601,997
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Keck *et al.*	
	FILING DATE December 15, 2000	GROUP 1645

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AT	Baier *et al.*, "Construction and Characterization of *lck*- and *fyn*-Specific tRNA:Ribozyme Chimeras," *Molecular Immunology* 31(12): 923-932 (1994).
	AU	Bates *et al.*, "Energy Coupling in *Escherichia coli* DNA Gyrase: the Relationship between Nucleotide Binding, Stand Passage, and DNA Supercoiling," *Biochemistry* 35:1408-16 (1996).
	AV	Bennett *et al.*, "Selective cleavage of closely-related mRNAs by synthetic ribozymes," *Nucleic Acids Research* 20(4): 831-7 (1992).
	AW	Betrand *et al.*, "Can hammerhead ribozymes be efficient tools to inactivate gene function," *Nucleic Acids Research* 22(3): 293-300 (1994).
	AX	Birikh *et al.*, "The structure, function and application of the hammerhead ribozyme," *European Journal of Biochemisty* 245: 1-16 (1997).
	AY	Cameron, F.H. and P.A. Jennings, "Specific gene suppression by engineered ribozymes in monkey cells," *Proc. Natl. Acad. Sci. USA* 86: 9139-9143 (1989).
	AZ	Cech, T.R., "Ribozyme engineering," *Current Opinion in Structural Biology* 2: 605-9 (1992).
	BA	Chen *et al.*, "Efficient hammerhead ribozyme and antisenses RNA targeting in a slow ribosome *Escherichia coli* mutant," *Nature Biotechnology* 15:432-5 (1997).
	BB	Chowrira *et al.*,"*In Vitro* and *In Vivo* Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-processing Ribozyme Cassettes," *J.Biol.Chem.* 269(41): 25856-64 (1994).
	BC	Cochran *et al.* "Eukaryotic transient expression system dependant on transcription factors and regulatory DNA sequences of vaccinia virus," *Proc. Natl. Acad. Sci. USA* 82:19-23 (1985).
	BD	Coffin *et al.* (Eds.) *Retroviruses* New York: Cold Spring Harbor Laboratory Press, 1997.
	BE	Couture, L.A. and D.T. Stinchcomb, "Anti-gene therapy: the use of ribozymes to inhibit gene function," *Trends in Genetics* 12(12): 510-5 (1996).
	BF	Danos, O. and R.C. Mulligan, "Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges," *Proc. Natl. Acad. Sci. USA* 85: 6460-4 (1988).
	BG	Derwent #010354638, WPI Acc. No.: 1995-255952/199534, for German Patent Publication DE 4424762 C and PCT Patent Publication WO 9601314 A2, "Ribozyme library in optimised expression cassete - comprises central hammerhead region and variable flanking regions, allows selection of optium ribozyme for specific applications".

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24743-2307US	SERIAL NO. 09/601,997
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Keck *et al.*	
	FILING DATE December 15, 2000	GROUP 1645

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BH	Derwent #010114899, WPI Acc. No.: 1995-016150/199503, for PCT Patent Publication WO 9428152 A1, "Non-replicating adenovirus derivs. - useful as vectors for exogenous genes".
	BI	Derwent #010305449, WPI Acc. No.: 1995-206709/199527, for PCT Patent Publication WO 9514101 A, "New recombinant adenovirus for gene therapy of cancer - contains heterologous sequence, e.g. for thymidine kinase or a ribozyme, controlled by sequences active specifically in tumour cells".
	BJ	Derwent #010305450, WPI Acc. No.: 1995-206710/199527, for PCT Patent Publication WO 9514102 A, "New defective adenovirus contg. gene for thymidine kinase - useful in gene therapy for treating or preventing cancer or viral infections".
	BK	Derwent #010642759, WPI Acc. No.: 1996-139713/199614, for PCT Patent Publciation WO 9605321 A, "Use of defective, recombinant adenovirus carrying suicide gene - for gene therapy of restenosis by transferring selected genes to smooth muscle cells of atherosclerotic plaque".
	BL	Fedor, M.J. and O.C. Uhlenbeck, "Substrate sequence effectson "hammerhead" RNA catalytic efficiency," *Proc. Natl. Acad. Sci. USA* 87: 1668-1672 (1990).
	BM	Feliciello, I. and G. Chinali, "A modified alkaline lysis method for the preparation of highly purified plasmid DNA from *Escherichia coli*," *Analytical Biochemistry* 212: 394-401 (1993).
	BN	Finer *et al.*,"*kat:* A High-Efficiency Retroviral Transduction System for Primary Human T Lymphocytes," *Blood* 83(1): 43-50 (1994).
	BO	Forster, A.C. and S. Altman, "External Guide Sequences for an RNA enzyme," *Science* 249: 783-6 (1990).
	BP	Gibson, S.A. and E.J. Shillitoe, "Ribozymes," *Molecular Biotechnology* 7: 125-37 (1997).
	BQ	Goldsmith, M.A. and A. Weiss, "Isolation and characterization of a T-lymphocyte somatic mutant with altered signal transduction by the antigen receptor," *Proc. Natl. Acad. Sci. USA* 84: 6879-83 (1987).
	BR	Hahn *et al.*, "Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation," *Proc. Natl. Acad. Sci. USA* 89: 2679-83 (1992).
	BS	Halbert *et al.*, "Transduction by Adeno-Associated Virus Vectors in the Rabbit Airway: Efficiency, Persistance, and Readministration," *Journal of Virolog* 71(8): 5932-41 (1997).
	BT	Hall *et al.*, "An approach to High-Throughput Genotyping," *Genome Research* 6: 781-90 (1996).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24743-2307US	SERIAL NO. 09/601,997
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Keck *et al.*	
	FILING DATE December 15, 2000	GROUP 1645

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BU	Haseloff, J. and W.L. Gerlach, "Simple RNA enzymes with new and highly specific endoribonuclease activities," *Nature* 334: 585-91 (1988).
	BV	Hofmann *et al.* "Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette," *Proc. Natl. Acad. Sci. USA* 93: 5185-90 (1996).
	BW	Huang, M. and J. Summers, "Infection Initiated by the RNA Pregenome of a DNA Virus," *Journal of Virology* 65(10): 5435-9 (1991).
	BX	Ishizaka *et al.*, "Isolation of Active Ribozymes from an RNA pool of Random Sequences Using an Anchored Substrate RNA," *Biochemical and Biophysical Research Communications* 214(2): 403-9 (1995).
	BY	Jayawickreme, C.K. and T.A. Kost, "Gene expression systems in the development of high-throughput screens," *Current Opinion in Biotechnology* 8: 629-34 (1997).
	BZ	Johnson *et al.*, "Identification of Zinc Finger mRNAs Using Domain-Specific Differential Display," *Analytical Biochemistry* 236: 348-52 (1996).
	CA	Kashani-Sabet, M and K.J. Scanlon, "Application of ribozymes to cancer gene therapy," *Cancer Gene Therapy* 2(3): 213-23 (1995).
	CB	Kawasaki *et al.*, "Selection of the best target site for ribozyme-mediated cleavage within a fusion gene for adenovirus E1A-associated 300 kDa protein (p300) and luciferase," *Nucleic Acids Research* 24(15): 3010-6 (1996).
	CC	Keck *et al.*, "Role of DNA Replication in Vaccinia Virus Gene Expression: A Naked Template is Required for Transcription of Three Late *Trans*-Activator Genes," *Cell* 61: 801-9 (1990).
	CD	Kijima *et al.*, "Therapeutic Applications of Ribozymes," *Pharmac. Ther.* 68: 247-67 (1995).
	CE	Kitamura *et al.*, "Efficient screening of retroviral cDNA expression libraries," *Proc. Natl. Acad. Sci. USA* 92: 9146-50 (1995).
	CF	Koizumi *et al.*, "Design of RNA enzymes distinguishing a single base mutation in RNA," *Nucleic Acids Research* 17(17): 7059-7071 (1989).
	CG	Lieber, A. and M. Strauss, "Selection of Efficient Cleavage Sites in Target RNAs by Using a Ribozyme Expression Library," *Molecular and Cellular Biology* 15(1): 540-51 (1995).
	CH	Lieber, A. and M.A. Kay, "Adenovirus-Mediated Expression of Ribozymes in Mice," *Journal of Virology* 70(5): 3153-8 (1996).
	CI	Markowitz *et al.*, "A Safe Packaging Line for Gene Transfer: separating Viral Genes on Two Different Plasmids," *Journal of Virology* 62(4): 1120-4 (1988).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24743-2307US	SERIAL NO. 09/601,997
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Keck *et al.*	
	FILING DATE December 15, 2000	GROUP 1645

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CJ	Markowitz *et al.*, "Construction and Use of a Safe and Efficient Amphotrophic Packaging Cell Line," *Virology* 167: 400-6 (1988).
	CK	McCall *et al.*, "Minimal sequence requirements for ribozyme activity," *Proc. Natl. Acad. Sci. USA* 89: 5710-4 (1992).
	CL	Miller *et al.*, "Cell-surface receptors for retroviruses and implications for gene transfer," *Proc. Natl. Acad. Sci. USA* 93:11407-13 (1996).
	CM	Miller, D.G. and A.D. Miller, "A Family of Retroviruses That Utilize Related Phosphate Transporters for Cell Entry," *Journal of Virology* 68(12): 8270-6 (1994).
	CN	Miller, A.D., "Human gene therapy comes of age," *Nature* 357: 455-60 (1992).
	CO	Miller, A.D and G.J. Rosman, "Improved Retroviral Vectors for Gene Transfer," *Biotechniques* 7: 980-90 (1989).
	CP	Miller, A.D. and C. Buttimore, "Redesign of Retrovirus Packaging Cell Lines To Avoid Recombination Leading to Helper Virus Production," *Molecular and Cellular Biology* 6(8): 2895-902 (1986).
	CQ	Mizuuchi *et al.*, "Cloning and Simplified Purification of *Escherichia coli* DNA Gyrase A and B Proteins," *The Journal of Biological Chemistry* 259(14): 9199-201 (1984).
	CR	Murphy, F.L. and T.R. Cech, "Alteration of substrate specificity for teh endoribonucleotide cleavage of RNA by the *Tetrahymena* ribozyme," *Proc. Natl. Acad. Sci. USA* 86: 9218-22 (1989).
	CS	Muzyczka, N., "Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells," *Current Topics in Microbiology and Immunology* 158: 97-123 (1992).
	CT	Pear *et al.*, "Production of high-titer helper-free retroviruses by transient transfection," *Proc. Natl. Acad. Sci. USA* 90: 8392-6 (1993).
	CU	Perreault *et al.*, "Relationship between 2'-Hydroxyls and Magnesium Binding in the Hammerhead RNA Domain: A Model for Ribozyme Catalysis," *Biochemisty* 30: 4020-5 (1991).
	CV	Perriman *et al.*, "Extended target-site specificity for an hammmerhead ribozyme," *Gene* 113: 157-63 (1992).
	CW	Peterson, F.C. and C.L. Brooks, "Identification of a Motif Associated with the Latogneic Actionsof Human Growth Hormone," *The Journal of Biological Chemistry* 272(34): 21444-8 (1997).
	CX	Rossi, J.J., "Controlled, targeted, intracellular expression of ribozymes: progress and problems," *Trends in Biotechnology* 13: 301-6 (1995).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24743-2307US	SERIAL NO. 09/601,997
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Keck *et al.*	
	FILING DATE December 15, 2000	GROUP 1645

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CY	Ruffner *et al.*, "Sequence Requirements of the Hammerhead RNA Self-Cleavage Reaction," *Biochemistry* 29: 10695-702 (1990).
	CZ	Sambrook, Fritsch, and Maniatis (Eds.) *Molecular Cloning: A Laboratory Manual* 2nd ed. New York: Cold Spring Harbor Laboratory Press, 1989 pgs. 7.6-7.29 and 7.37-7.57
	DA	Samulski *et al.*, "Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression," *Journal of Virology* 63(9): 3822-8 (1989).
	DB	Schulte-Merker *et al.*, "The protein product of the zebrafish homologue of the mouse T gene is expressed in nuclei of the germ ring and the notochord of the early embryo," *Development* 116(4): 1021-33 (1992).
	DC	Sczakiel, G., "The Design of Antisense RNA," *Antisense & Nucleic Acid Drug Development* 7: 439-44 (1997).
	DD	Shore *et al.*, "Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity," *Oncogene* 8: 3183-8 (1993).
	DE	Sigurdsson, S.T. and F. Eckstein, "Structure-function relationships of hammerhead ribozymes: form understanding to applications," *Trends in Biotechnology* 13: 286-9 (1995).
	DF	Soares, M.B., "Identification and cloning of differentially expressed genes," *Current Opinion in Biotechnology* 8: 542-6 (1997).
	DG	Stoker, A.W., Chapter 6 "Retroviral vectors," of *Molecular Virology: A Practical Approach* Davidson, A.J. and R.M. Elliott (Eds.) Oxford: IRL Press, 1993 pgs. 171-197
	DH	Stone, B. and W. Wharton, "Targeted RNA fingerprinting: the cloning of differentially-expressed cDNA fragments enriched for members of the zinc finger gene family," *Nucleic Acids Research* 22(13): 2612-8 (1994).
	DI	Straus, D.B. and A. Weiss, "Genetic Evidence for the Involvement of the ICK Tyrosine Kinase in Signal Transduction through the T Cell Antigen Receptor," *Cell* 70: 585-93 (1992).
	DJ	Sullenger, B.A., "Colocalizing Ribozymes with Substrate RNAs to Increase Their Efficacy as Gene Inhibitors," *Applied Biochemisty and Biotechnology* 54: 57-61 (1995).
	DK	Sullenger *et al.*, "Expression of Chimeric tRNA-Driven Antisense Transcripts Renders NIH 3T3 Cells Highly Resistant to Moloney Murine Leukemia Virus Replication," *Molecular and Cellular Biology* 10(12): 6512-23 (1990).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24743-2307US	SERIAL NO. 09/601,997
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Keck *et al.*	
	FILING DATE December 15, 2000	GROUP 1645

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	DL	Sullenger, B.A. and T.R. Cech, "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA," *Science* 262: 1566-9 (1993).
	DM	Sun *et al.*, "Anti-HIV Ribozymes," *Molecular Biotechnology* 7: 241-51 (1997).
	DN	Sun *et al.*, "Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response elements constructs," *Proc. Natl. Acad. Sci. USA* 92: 7272-6 (1995).
	DO	Uhlenbeck, O.C., "A small catalytic oligoribonucleotide," *Nature* 328: 596-603 (1987).
	DP	Von Stein *et al.*, "A high throughput screening for rarely transcribed differentially expressed genes," *Nucleic Acids Research* 25(13): 2598-602 (1997).
	DQ	Weiss *et al.*, "Signal transduction by the T cell antigen receptor," *Seminars in Immunology* 3: 313-24 (1991).
	DR	Wyatt *et al.*, "Replication-Deficient Vaccinia Virus Encoding Bacteriophage T7 RNA Polymerase for Transient Gene Expression in Mammalian Cells," *Virology* 210: 202-5 (1995).
	DS	Xie *et al.*, "A ribozyme-mediated, gene "knockdown" strategy for the identification of gene functionin zebrafish," *Proc. Natl. Acad. Sci. USA* 94: 13777-81 (1997).
	DT	Xiong *et al.*, "Sindbis Virus: An Efficient, Broad Host Range Vetor for Gene Expression in Animal Cells," *Science* 243: 1188-91 (1989).
	DU	Zhao *et al.*, "Generating loss-of-function phenotypes of the *fushi tarazu* gene with a targeted ribozyme in *Drosophila*," *Nature* 365: 448-51 (1993).
	DV	Zhou *et al.*, "Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-*tat* and *rev* hammerhead ribozymes," *Gene* 149: 33-9 (1994).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.